|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Tieulent Lortet J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Japanese Gastric Cancer Association:
Japanese classification of gastric carcinoma: 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yashiro M, Chung YS, Nishimura S, Inoue T
and Sowa M: Fibrosis in the peritoneum induced by scirrhous gastric
cancer cells may act as ‘soil’ for peritoneal dissemination.
Cancer. 77:S1668–S1675. 1996. View Article : Google Scholar
|
|
4
|
Kitamura K, Beppu R, Anai H, Ikejiri K,
Yakabe S, Sugimachi K and Saku M: Clinicopathologic study of
patients with Borrmann type IV gastric carcinoma. J Surg Oncol.
58:112–117. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dohmen K, Mizukami Y, Tanaka K, Nakamura
H, Arase K, Yokogawa Y, Asayama R, Kato A, Kato M, Nakagaki M, et
al: Retroperitoneal fibrosis associated with scirrhous gastric
cancer. Gastroenterol Jpn. 28:699–705. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peixoto RD, Al Barrak J, Lim H and Renouf
D: Gastroesophageal cancer and retroperitoneal fibrosis: Two case
reports and review of the literature. World J Gastrointest Oncol.
5:68–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasaki T, Koizumi W, Higuchi K, Ishido K,
Ae T, Nakatani K, Katada C, Tanabe S and Saigenji K: Therapeutic
strategy for type 4 gastric cancer from the clinical oncologist
standpoint. Gan To Kagaku Ryoho. 34:988–992. 2007.(In Japanese).
PubMed/NCBI
|
|
8
|
Sawaki A, Yamaguchi K, Nabeya Y, Sakai Y,
Osanai H, Denda T, Furue H and Kurihara M: 5 FU/l LV(RPMI) versus S
1 as first line therapy in patients with advanced gastric cancer: A
randomized phase III non inferiority trial (ISO 5FU10 study group
trial). Eur J Cancer, Suppl. 7:3632009. View Article : Google Scholar
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Common Terminology Criteria for Adverse
Events (CTCAE). Version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009
05 29_QuickReference_8.5×11.pdfSeptember 5–2018
|
|
11
|
Hamamoto Y: Complications in advanced or
recurrent gastric cancer patients with peritoneal metastasis during
and after palliative systemic chemotherapy. Mol Clin Oncol.
3:539–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koep L and Zuidema GD: The clinical
significance of retroperitoneal fibrosis. Surgery. 81:250–257.
1977.PubMed/NCBI
|
|
13
|
Vaglio A, Salvarani C and Buzio C:
Retroperitoneal fibrosis. Lancet. 367:241–251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Webb AJ and Edwards Dawson P: Malignant
retroperitoneal fibrosis. Br J Surg. 54:505–508. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thomas MH and Chisholm GD: Retroperitoneal
fibrosis associated with malignant disease. Br J Cancer.
28:453–458. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cronin CG, Lohan DG, Blake MA, Roche C,
McCarthy P and Murphy JM: Retroperitoneal fibrosis: A review of
clinical features and imaging findings. AJR Am J Roentgenol.
191:423–431. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Usher SM, Brendler H and Ciavarra VA:
Retroperitoneal fibrosis secondary to metastatic neoplasm. Urology.
9:191–194. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yokoyama R, Tazaki R, Morita H, Nishitani
H, Ariumi S, Osuga S, Sohmiya K, Kono T, Narumi Y, Tsuji M, et al:
Retroperitoneal fibrosis in a patient with gastric cancer
manifested by lower extremity edema and hydrocele. Intern Med.
51:2157–2160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bisof V, Juretic A, Pasini J, Coric M,
Grgic M, Gamulin M, Rakusic Z, Krajina Z, Koretic Basic M, Misir A,
et al: Ureteral metastasis as the first and sole manifestation of
gastric cancer dissemination. Radiol Oncol. 44:262–264. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimoyama Y, Ohashi M, Hashiguchi N,
Ishihara M, Sakata M, Tamura A, Asato Y, Saitoh K and Mukai M:
Gastric cancer recognized by metastasis to the ureter. Gastric
Cancer. 3:102–105. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tahara M, Ohtsu A, Boku N, Nagashima F,
Muto M, Sano Y, Yoshida M, Mera K, Hironaka S, Tajiri H, et al:
Sequential methotrexate and 5 fluorouracil therapy for gastric
cancer patients with peritoneal dissemination: A retrospective
study. Gastric Cancer. 4:212–218. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dupont JB Jr, Lee JR, Burton GR and Cohn I
Jr: Adenocarcinoma of the stomach: Review of 1,497 cases. Cancer.
41:941–947. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shirao K, Boku N, Yamada Y, Yamaguchi K,
Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, et al:
Gastrointestinal Oncology Study Group of the Japan Clinical
Oncology Group: Randomized Phase III study of 5 fluorouracil
continuous infusion vs. sequential methotrexate and 5 fluorouracil
therapy in far advanced gastric cancer with peritoneal metastasis
(JCOG0106). Jpn J Clin Oncol. 43:972–980. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishina T, Boku N, Gotoh M, Shimada Y,
Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K, et
al: Gastrointestinal Oncology Study Group of the Japan Clinical
Oncology Group: Randomized phase II study of second line
chemotherapy with the best available 5 fluorouracil regimen versus
weekly administration of paclitaxel in far advanced gastric cancer
with severe peritoneal metastases refractory to 5 fluorouracil
containing regimens (JCOG0407). Gastric Cancer. 19:902–910. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iwasa S, Nakajima TE, Nakamura K,
Takashima A, Kato K, Hamaguchi T, Yamada Y and Shimada Y: Systemic
chemotherapy for peritoneal disseminated gastric cancer with
inadequate oral intake: A retrospective study. Int J Clin Oncol.
16:57–62. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Superfin D, Iannucci AA and Davies AM:
Commentary: Oncologic drugs in patients with organ dysfunction: a
summary. Oncologist. 12:1070–1083. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Field KM, Michael M and Part II: Part II:
Liver function in oncology: Towards safer chemotherapy use. Lancet
Oncol. 9:1181–1190. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Janus N, Thariat J, Boulanger H, Deray G
and Vacher Launay V: Proposal for dosage adjustment and timing of
chemotherapy in hemodialyzed patients. Ann Oncol. 21:1395–1403.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shimada H, Noie T, Ohashi M, Oba K and
Takahashi Y: Clinical significance of serum tumor markers for
gastric cancer: A systematic review of literature by the Task Force
of the Japanese Gastric Cancer Association. Gastric Cancer.
17:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stahl A, Ott K, Weber WA, Becker K, Link
T, Siewert JR, Schwaiger M and Fink U: FDG PET imaging of locally
advanced gastric carcinomas: Correlation with endoscopic and
histopathological findings. Eur J Nucl Med Mol Imaging. 30:288–295.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burgain C, Germain A, Bastien C, Orry X,
Choné L, Claudon M and Laurent V: Computed tomography features of
gastrointestinal linitis plastica: Spectrum of findings in early
and delayed phase imaging. Abdom Radiol (NY). 41:1370–1377. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Agnes A, Estrella JS and Badgwell B: The
significance of a nineteenth century definition in the era of
genomics: Linitis plastica. World J Surg Oncol. 15:1232017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Japanese gastric cancer association.
Japanese gastric cancer treatment guidelines 2014 (ver.4). Gastric
Cancer. 20:1–19. 2017. View Article : Google Scholar
|
|
34
|
NCCN Clinical Practice Guideline in
Oncology (NCCN Guidelines®). version 5.2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5×11.pdfDecember
7–2017
|
